Uncoupling of proopiomelanocortin (POMC) fragments is related to self- injury

Peptides

Volumn 21, Issue 6, 2000, Pages 785-791

  Sandman, Curt A ^a,b   Hetrick, William ^c   Talyor, Derek ^b   Marion, Sarah ^b   Chicz Demet, Aleksandra ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fairview Developmental Center   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

endorphin; ACTH; Autism; Naltrexone; Opioids; POMC; Self injury

Indexed keywords

BETA ENDORPHIN; CORTICOTROPIN; NALTREXONE; OPIATE ANTAGONIST; PEPTIDE FRAGMENT; PROOPIOMELANOCORTIN;

ARTICLE; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION;

ADRENOCORTICOTROPIC HORMONE; AUTISTIC DISORDER; BETA-ENDORPHIN; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; PEPTIDE FRAGMENTS; PRO-OPIOMELANOCORTIN; SELF-INJURIOUS BEHAVIOR;

EID: 0033843726     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(00)00209-6     Document Type: Article

References (33)

1. Banks W.A., Audus K.L., Davis T.P. Permeability of the blood-brain barrier to peptides an approach to the development of therapeutically useful analogs . Peptides. 13:1992;1289-1294.
2. Barron J.L., Sandman C.A. Relationship of sedative-hypnotic response to self-injurious behavior and stereotypy in mentally retarded clients. Am J Ment Retard. 88:1983;177-186.
3. Barron J.L., Sandman C.A. Self-injurious behavior and stereotypy in institutionalized mentally retarded population. Am J Ment Retard. 5:1984;499-511.
4. Barron J.L., Sandman C.A. Paradoxical excitement to sedative-hypnotics in mentally retarded clients. Am J Mental Retard. 2:1985;124-129.
5. Bertagna X. Proopiomelanocortin-derived peptides. Endocrin Metab Clin North Am. 23:1994;467-485.
6. Bicknell A.B., Savva D., Lowry P.J. Pro-opiomelanocortin and adrenal function. Endocr Res. 22:1996;385-393.
7. Boutillier A.L., Monnier D., Lorang D., Lundblad J.R., Roberts J.L., Loeffler J.P. Corticotropin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways characterization of an AP1 site in exon 1 . Mol Endocrinol. 9:1995;745-755.
8. Bouvard M.P., Leboyer M., Launay J.M., et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism a double-blind, placebo-controlled study . Psych Res. 58:1995;191-201.
9. Crain S.M., Shen K.F. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci USA. 92:1995;10540-10544.
10. Ernst M., Devi L., Silva R.R., et al. Plasma β-endorphin levels, naltrexone, and Haloperidol in autistic children. Psychopharmacol Bull. 29:1993;221-227.
11. Gen K., Toshiaki H., Kato T., Kato Y. Presence of the same transcript of pro-opiomelanocortin (POMC) genes in the porcine anterior and intermediate pituitary lobes. Mol Cell Endocrinol. 103:1994;101-108.
12. Hetrick W.P., Isenhart R.C., Taylor D.V., Sandman C.A. ODAP. A stand-alone program for observational data acquisition. Behav Res Meth Instruments Comput. 23:1991;66-71.
13. Kastin A.J., Pearson M.A., Banks W.A. EEG evidence that morphine and an enkephalin analog cross the blood-brain barrier. Pharmacol Biochem Behav. 40:1991;771-774.
14. LeBoyer M., Bouvard M.P., Recasens C., et al. Difference between plasma N- and C-terminally directed β-endorphin immunoreactivity in infantile autism. Am J Psych. 151:1994;1797-1801.
15. Leboyer M., Philippe A., Bouvard M., et al. Whole blood serotonin and plasma β-endorphin in autistic probands and their first-degree relatives. Biol Psych. 45:1999;158-163.
16. Marley R.J., Shimosato K., Gewiss M., Thorndike E., Goldberg S.R., Schindler C.W. Long-term sensitization to the behavioral effects of naltrexone is associated with regionally specific changes in the number of μ and δopioid receptors in rat brain. Life Sci. 56:1995;767-774.
17. Mutti A., Ferroni C., Vescovi P.P., et al. Endocrine effects of psychosocial stress associated with neurobehavioral performance testing. Life Sci. 44:1989;1831-1836.
18. Reisine T., Pasternak G. Opioid analgesics and antagonists. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. The pharmacological basis of therapeutics. 1996;521-556 McGraw-Hill, New York.
19. Sandman C.A., Barron J.L. Paradoxical response to sedative/hypnotics in patients with self-injurious behavior and stereotypy. J Dev Phys Disabil. 4:1992;1-10.
20. Sandman CA, Hetrick WP. Opiate mechanisms in self-injury. Ment Retard Dev Disabil Res Rev 1995;1:130-6.
21. Sandman C.A., Hetrick W.P., Taylor D.V., et al. Naltrexone reduces self-injury and improves learning. Exp Clin Psychopharmacol. 1:1993;242-258.
22. Sandman C.A., Hetrick W.P., Taylor D.V., Chicz-DeMet A. Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers. Am J Ment Retard. 102:1997;182-199.
23. Sandman CA, Hetrick WP, Taylor DV, et al. Long-term effects of naltrexone on self-injurious behavior. Am J Ment Retard, In press.
24. Sandman C.A., Smith M., Spence A. Proopiomelanocortin (POMC) disregulation and response to opiate blockers. Ment Retard Dev Disabil Res Rev. 5:1999;314-321.
25. Sandman C.A., Wadhwa P., Chicz-DeMet A., Porto M., Garite T. Third trimester POMC disregulation predicts use of anesthesia at birth. Peptides. 16:1995;187-190.
26. Schaefer G.J., Michael R.P. Interactions of naloxone with morphine, amphetatine, and phencyclide on fixed interval responding for intracranial (i.c.) self-stimulation in rats. Psychopharmacology. 102:1990;263-268.
27. Schulte H.M., Allolio B. Infusion of β-endorphin has no suppressive effect on the releasing hormone-stimulated pituitary-adrenal-axis of normal human subjects. Acta Endocrinol (Copenh). 1:1990;526-530.
28. Seidah N.G., Chretien M. Proprotein and prohormone convertases of the subtilisin family. Trends Endocrinol Metabol. 3:1992;133-140.
29. Seidah N.G., Marcinkiewicz M., Benjannet S., et al. Cloning and primary sequence of a mouse candidate prohormone convertase PC1 homologous to PC2, Furin, and KEX 2 distinct chromosomal localization and messenger RNA distribution in brain and pituitary compared to PC2 . Mol Endocrinol. 5:1991;111-122.
30. Shen K., Crain S.M. Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid dependence without tolerance. Brain Res. 597:1992;74-83.
31. Strand FL. Neuropeptides. Regulators of physiological processes. Cambridge, MA: MIT Press.
32. Wadhwa P.D., Dunkel-Schetter C., Chicz-DeMet A., Porto M., Sandman C.A. Prenatal psychosocial factors and the neuroendocrine axis in human pregnancy. Psychosom Med. 58:1996;432-446.
33. Zheng M., Streck R.D., Scott R.E., Seidah N.G., Pintar J.E. The developmental expression in rat of proteases furin, PC1, PC2, and carboxypeptidase E implications for early maturation of proteolytic processing capacity . J Neurosci. 14:1994;4656-4673.